Verastem Oncology to Host Investor Conference Call and Report Updated Data and Progress Across VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor TARGET-D Clinical Program

Key Takeaway: Verastem Oncology is set to host an investor conference call to discuss updated data and progress on their VS-7375 oral KRAS G12D inhibitor within the TARGET-D clinical program. The event aims to provide insights into the ongoing developments and future directions of this therapeutic approach.